611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Widely Used Antipsychotics May Not Ease Delirium in ICUDisabling Hip Ailment Is Another Health Risk for Obese KidsE-Cigarettes Slowed Wound Healing in Animal Study3-Drug Therapy Might Be Cystic Fibrosis 'Breakthrough'Pounds Regained After Weight-Loss Op Can Tell Your Doc a LotCDC Warns of Polio-Like Virus Striking More U.S. KidsNew Nerve Stimulation Technique Might Relieve Back PainGluten-Free Craze a 'Double-Edged Sword' for Celiac PatientsHealth Tip: Know the Risks of Chicken PoxKids' Concussion Symptoms May Persist for a YearNew DNA-Based Test Approved to Help Verify Blood CompatibilityAHA: A Child's Eyes May Be a Window Into Later Heart Disease RiskGenes, Not Diet, May Be Key to Gout Flare-UpsDiabetes Drug Might Help Shield the Heart From Smog's Ill EffectsHealth Tip: Understanding MigrainesHospital Privacy Curtains May Be Home to Dangerous GermsWeight-Loss Surgery May Raise Gallstone Risk: StudyStudy Sees No Link Between Gout Drug, Kidney DiseaseHealth Tip: Prevent Mold Growth at HomeOne-Third of 'Gluten-Free' Restaurant Foods in U.S. Are Not: StudyHalf of Antibiotics Given Without Infection DiagnosisMediterranean Diet May Help Preserve Your Vision: StudyAHA: Researchers Suggest New Way to Possibly Eliminate Clogged ArteriesCan a 'Noah's Ark' of Microbes Save the World's Health?Brain Scans Suggest Pain of Fibromyalgia Isn't ImaginaryHealth Tip: Treat Your Child's AllergiesAHA: Doctors Could Do More to Help Smokers With Poor CirculationAcne's Stigma Can Take a Big Mental TollDoes Less-Invasive Surgery Make Sense for You?Type 2 Diabetes Tied to Raised Risk of Tumors, Cancer Deaths'Southern' Diet Blamed for Black Americans' Health WoesOne Football Rule Change Might Lower Concussion RiskDeep Space Travel May Damage GI Tract, Animal Study ShowsNew Drug Approved for Antibiotic-Resistant Lung DiseaseDrinking Enough Water Could Be Key to Avoiding UTIsThree New Genes Linked to Chronic Back Pain'Yo-Yo' Cardio Readings May Signal Heart RisksHealth Tip: Understanding Hip Replacement SurgeryCommon Heartburn Drugs Linked to Broken Hips in Dialysis PatientsWith 80,000 Flu Deaths Last Season, Experts Urge VaccinationHealth Tip: Manage Symptoms of AnemiaHealth Tip: Considering LASIK Surgery?Don't Turn a Blind Eye to Vision ProblemsExperimental Vaccine Shows Promise in Preventing TBAntibiotics May Cure Appendicitis -- No Operation NeededGun Victims More Likely to Die Than Other Trauma PatientsSpinal Implant Could Be Breakthrough for Paralyzed PatientsHealth Tip: Maintain Healthy Cholesterol5 Tips to Manage Your Child's AsthmaNew Compounds Might Help Stop Spread of Malaria
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Peanut Patch Found Safe, Effective for Treating Allergies


HealthDay News
Updated: Nov 15th 2017

new article illustration

WEDNESDAY, Nov. 15, 2017 (HealthDay News) -- A 250-μg peanut patch produces a significant treatment response in peanut-allergic patients treated for a year, according to a study published online Nov. 14 in the Journal of the American Medical Association.

Hugh A. Sampson, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a multicenter phase 2b trial to determine the optimal dose, adverse events (AEs), and efficacy of a peanut patch for treatment of peanut-allergic patients (aged 6 to 55 years). Patients were randomly assigned to receive an epicutaneous peanut patch containing 50, 100, or 250 μg of peanut protein (n = 53, 56, and 56, respectively) or a placebo patch (n = 56). After 12 months of daily patch application, patients underwent a placebo-controlled food challenge to determine an eliciting dose.

The researchers found that a significant absolute difference in response rates was seen at month 12 between the 250-μg patch and the placebo patch (50 versus 25 percent), but no significant difference was seen between the placebo patch and the 100-μg patch. The only significant interaction by age group was for the 250-μg patch; the response rate difference in the 6- to 11-year stratum was 34.2 percent between the 250-μg patch and placebo. There were no dose-related serious adverse events reported.

"In this dose-ranging trial of peanut-allergic patients, the 250-μg peanut patch resulted in significant treatment response versus placebo patch following 12 months of therapy. These findings warrant a phase 3 trial," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including DBV Technologies, which funded the study.

Abstract/Full Text (subscription or payment may be required)